POEMS Syndrome-Clinical Picture and Management. Current Knowledge
Clin Lymphoma Myeloma Leuk. 2023 Apr 26:S2152-2650(23)00136-2. doi: 10.1016/j.clml.2023.04.008. Online ahead of print.ABSTRACTPOEMS syndrome is a rare form of plasma cell dyscrasia. Difficulties arise already at the stage of making the diagnosis (complex and heterogeneous clinical picture) and continue during the course of treatment (lack of guidelines for therapy, data coming mainly from reports and short series of patients). In this article we review the current state of knowledge on POEMS syndrome diagnostics, clinical characteristics, prognosis, reported treatment outcomes and the emergence of the new therapeutic strat...
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Artur Jurczyszyn Magdalena Olszewska-Szopa David Vesole Source Type: research
Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population
CONCLUSION: In a non-Asian population, the mSMILE regimen with PEG-asparaginase is a safe alternative to the L-asparaginase-based SMILE regimen. There is a comparable risk of hematological toxicity, and no treatment-related mortality was seen in our population.PMID:37210271 | DOI:10.1016/j.clml.2023.04.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Amin Azem Ryan Caddell Rebecca Nelson Leidy Isenalumhe Sameh Gaballa Julio Chavez Celeste Bello Javier Pinilla Lubomir Sokol Bijal Shah Hayder Saeed Source Type: research
POEMS Syndrome-Clinical Picture and Management. Current Knowledge
Clin Lymphoma Myeloma Leuk. 2023 Apr 26:S2152-2650(23)00136-2. doi: 10.1016/j.clml.2023.04.008. Online ahead of print.ABSTRACTPOEMS syndrome is a rare form of plasma cell dyscrasia. Difficulties arise already at the stage of making the diagnosis (complex and heterogeneous clinical picture) and continue during the course of treatment (lack of guidelines for therapy, data coming mainly from reports and short series of patients). In this article we review the current state of knowledge on POEMS syndrome diagnostics, clinical characteristics, prognosis, reported treatment outcomes and the emergence of the new therapeutic strat...
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Artur Jurczyszyn Magdalena Olszewska-Szopa David Vesole Source Type: research
Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population
CONCLUSION: In a non-Asian population, the mSMILE regimen with PEG-asparaginase is a safe alternative to the L-asparaginase-based SMILE regimen. There is a comparable risk of hematological toxicity, and no treatment-related mortality was seen in our population.PMID:37210271 | DOI:10.1016/j.clml.2023.04.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Amin Azem Ryan Caddell Rebecca Nelson Leidy Isenalumhe Sameh Gaballa Julio Chavez Celeste Bello Javier Pinilla Lubomir Sokol Bijal Shah Hayder Saeed Source Type: research
POEMS Syndrome-Clinical Picture and Management. Current Knowledge
Clin Lymphoma Myeloma Leuk. 2023 Apr 26:S2152-2650(23)00136-2. doi: 10.1016/j.clml.2023.04.008. Online ahead of print.ABSTRACTPOEMS syndrome is a rare form of plasma cell dyscrasia. Difficulties arise already at the stage of making the diagnosis (complex and heterogeneous clinical picture) and continue during the course of treatment (lack of guidelines for therapy, data coming mainly from reports and short series of patients). In this article we review the current state of knowledge on POEMS syndrome diagnostics, clinical characteristics, prognosis, reported treatment outcomes and the emergence of the new therapeutic strat...
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Artur Jurczyszyn Magdalena Olszewska-Szopa David Vesole Source Type: research
Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population
CONCLUSION: In a non-Asian population, the mSMILE regimen with PEG-asparaginase is a safe alternative to the L-asparaginase-based SMILE regimen. There is a comparable risk of hematological toxicity, and no treatment-related mortality was seen in our population.PMID:37210271 | DOI:10.1016/j.clml.2023.04.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Amin Azem Ryan Caddell Rebecca Nelson Leidy Isenalumhe Sameh Gaballa Julio Chavez Celeste Bello Javier Pinilla Lubomir Sokol Bijal Shah Hayder Saeed Source Type: research
POEMS Syndrome-Clinical Picture and Management. Current Knowledge
Clin Lymphoma Myeloma Leuk. 2023 Apr 26:S2152-2650(23)00136-2. doi: 10.1016/j.clml.2023.04.008. Online ahead of print.ABSTRACTPOEMS syndrome is a rare form of plasma cell dyscrasia. Difficulties arise already at the stage of making the diagnosis (complex and heterogeneous clinical picture) and continue during the course of treatment (lack of guidelines for therapy, data coming mainly from reports and short series of patients). In this article we review the current state of knowledge on POEMS syndrome diagnostics, clinical characteristics, prognosis, reported treatment outcomes and the emergence of the new therapeutic strat...
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Artur Jurczyszyn Magdalena Olszewska-Szopa David Vesole Source Type: research
Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population
CONCLUSION: In a non-Asian population, the mSMILE regimen with PEG-asparaginase is a safe alternative to the L-asparaginase-based SMILE regimen. There is a comparable risk of hematological toxicity, and no treatment-related mortality was seen in our population.PMID:37210271 | DOI:10.1016/j.clml.2023.04.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Amin Azem Ryan Caddell Rebecca Nelson Leidy Isenalumhe Sameh Gaballa Julio Chavez Celeste Bello Javier Pinilla Lubomir Sokol Bijal Shah Hayder Saeed Source Type: research
POEMS Syndrome-Clinical Picture and Management. Current Knowledge
Clin Lymphoma Myeloma Leuk. 2023 Apr 26:S2152-2650(23)00136-2. doi: 10.1016/j.clml.2023.04.008. Online ahead of print.ABSTRACTPOEMS syndrome is a rare form of plasma cell dyscrasia. Difficulties arise already at the stage of making the diagnosis (complex and heterogeneous clinical picture) and continue during the course of treatment (lack of guidelines for therapy, data coming mainly from reports and short series of patients). In this article we review the current state of knowledge on POEMS syndrome diagnostics, clinical characteristics, prognosis, reported treatment outcomes and the emergence of the new therapeutic strat...
Source: Clinical Lymphoma and Myeloma - May 20, 2023 Category: Cancer & Oncology Authors: Artur Jurczyszyn Magdalena Olszewska-Szopa David Vesole Source Type: research
Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study
CONCLUSION: As COVID-19 remains a looming health concern, especially amongst vulnerable populations, our analysis emphasizes the need for adequate vaccination and treatment regimens as well as an understanding of the severity of infection in MGUS patients and justification for precautionary measures.PMID:37208255 | PMC:PMC10140469 | DOI:10.1016/j.clml.2023.04.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 19, 2023 Category: Cancer & Oncology Authors: Omer S Ashruf Zara Orozco David C Kaelber Source Type: research
Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study
CONCLUSION: As COVID-19 remains a looming health concern, especially amongst vulnerable populations, our analysis emphasizes the need for adequate vaccination and treatment regimens as well as an understanding of the severity of infection in MGUS patients and justification for precautionary measures.PMID:37208255 | DOI:10.1016/j.clml.2023.04.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 19, 2023 Category: Cancer & Oncology Authors: Omer S Ashruf Zara Orozco David C Kaelber Source Type: research
Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte
CONCLUSIONS: We hypothesize that safe and superior immunotherapy of MDR with cure potential may be accomplished by IMAK, most probably in patients with low tumor burden, but that remains to be confirmed by future clinical trials.PMID:37202579 | DOI:10.1007/s00432-023-04780-5 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 18, 2023 Category: Cancer & Oncology Authors: Shimon Slavin Source Type: research
Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte
CONCLUSIONS: We hypothesize that safe and superior immunotherapy of MDR with cure potential may be accomplished by IMAK, most probably in patients with low tumor burden, but that remains to be confirmed by future clinical trials.PMID:37202579 | DOI:10.1007/s00432-023-04780-5 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 18, 2023 Category: Cancer & Oncology Authors: Shimon Slavin Source Type: research
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
CONCLUSION: The experience from our single institution pilot study suggested that sequential rather than alternating BR and cytarabine/rituximab (CR) was easier to administer from the standpoint of toxicities and subsequent dose modifications. Safety and efficacy data from the 2 pilot studies, FitMCL 1.0 and 2.0, were similar. The pilot studies provided preliminary safety data supporting the development of the NCTN trial EA4181, assessing three different induction regimens with or without acalabrutinib.PMID:37183115 | DOI:10.1016/j.clml.2023.04.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 14, 2023 Category: Cancer & Oncology Authors: Dilan A Patel Fei Wan Kathryn Trinkaus Daniel G Guy Natasha Edwin Marcus Watkins Nancy L Bartlett Amanda Cashen Todd A Fehniger Armin Ghobadi Neha-Mehta Shah Brad S Kahl Source Type: research
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
CONCLUSION: The experience from our single institution pilot study suggested that sequential rather than alternating BR and cytarabine/rituximab (CR) was easier to administer from the standpoint of toxicities and subsequent dose modifications. Safety and efficacy data from the 2 pilot studies, FitMCL 1.0 and 2.0, were similar. The pilot studies provided preliminary safety data supporting the development of the NCTN trial EA4181, assessing three different induction regimens with or without acalabrutinib.PMID:37183115 | DOI:10.1016/j.clml.2023.04.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 14, 2023 Category: Cancer & Oncology Authors: Dilan A Patel Fei Wan Kathryn Trinkaus Daniel G Guy Natasha Edwin Marcus Watkins Nancy L Bartlett Amanda Cashen Todd A Fehniger Armin Ghobadi Neha-Mehta Shah Brad S Kahl Source Type: research
